ArticleThe Journal of surgical research2025
Cost-Effectiveness and Cost Only Studies for Inflammatory Bowel Disease Surgery: A Scoping Review.
Article in The Journal of surgical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionStudies examining the cost-effectiveness of surgical procedures and surgery-related interventions in patients with inflammatory bowel disease (IBD) remain limited. This dearth of studies hampers decision-makers' assessment of surgery-related interventions for patients with IBD. This study aimed to conduct a scoping review of the available literature for cost-effectiveness analyses of IBD-related surgery.
methodsWe performed a comprehensive search in common publication registries. Preplanned controlled vocabulary related to IBD and its subtypes, surgery, and cost measures were used. We defined the study selection criteria to include all IBD-related surgical interventions that also reported a measure of costs of care. Studies for medical versus surgical interventions for refractory IBD were excluded. All search findings were screened by two reviewers using titles, abstracts, and ultimately full-length manuscripts. Fully screened studies were then extracted to facilitate a qualitative synthesis of results.
resultsWe identified seven formal cost-effectiveness studies and 55 cost only studies. Cost-effectiveness studies assessed intraoperative (42.9%) and postoperative interventions (57.1%), mostly in patients with Crohn's disease (71.4%). Topics included surgical approaches (42.8%), venous thromboembolism prophylaxis (28.6%), and surveillance for postoperative recurrence (28.6%). Of the cost only studies, most focused on intraoperative interventions (81.8%), particularly in ulcerative colitis patients (45.5%). Predefined areas with no reported interventions included enhanced recovery interventions, robotic surgery, timing to surgery, perianal disease, pediatric disease, and genetic testing.
conclusionsThis scoping review found minimal cost-effectiveness literature to inform IBD-related surgical care. There were many more cost only studies than cost-effectiveness studies related to these clinical topics. This asymmetry highlights immediately available opportunities to broaden the use of cost-effectiveness analyses for IBD-related surgical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.